Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.3.2.10 - soluble epoxide hydrolase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acute Coronary Syndrome
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.
Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.
[Effects of soluble epoxide hydrolase inhibitors on the expression of fatty acid synthase in peripheral blood mononuclear cell of patients and inflammatory response with acute coronary syndrome].
Acute Kidney Injury
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery.
Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
Acute Lung Injury
Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.
Effect of Soluble Epoxide Hydrolase in Hyperoxic Acute Lung Injury in Mice.
Effects of a Soluble Epoxide Hydrolase Inhibitor on Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages.
Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.
Adenocarcinoma
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Adenoma
Epoxide hydrolase polymorphisms, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study.
Levels of cytochrome P-450, steroidogenesis and microsomal and cytosolic epoxide hydrolases in normal human adrenal tissue and corresponding tumors.
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Albuminuria
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
Alveolar Bone Loss
Soluble epoxide hydrolase pharmacological inhibition decreases alveolar bone loss by modulating host inflammatory response, RANK-related signaling, ER stress and apoptosis.
Alzheimer Disease
14,15-epoxyeicosatrienoic acid alleviates pathology in a mouse model of Alzheimer's disease.
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease.
Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer's disease.
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease.
Anemia, Aplastic
Glutathione S transferase theta 1 gene (GSTT1) null genotype is associated with an increased risk for acquired aplastic anemia in children.
Aneurysm
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Aortic Aneurysm, Abdominal
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
arachidonate 12-lipoxygenase deficiency
Inhibition of 12/15-Lipoxygenase Reduces Renal Inflammation and Injury in Streptozotocin-Induced Diabetic Mice.
Arrhythmias, Cardiac
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.
Arthralgia
Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis.
Arthritis
Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats.
Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model.
Asthma
Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance.
Inhibition of soluble epoxide hydrolase attenuates airway remodeling in a chronic asthma model.
Interactions between polycyclic aromatic hydrocarbons and epoxide hydrolase 1 play roles in asthma.
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.
Atherosclerosis
A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro.
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
Effects of soluble epoxide hydrolase inhibitor on the expression of fatty acid synthase in peripheral blood mononuclear cell in patients with acute coronary syndrome.
Endothelial Nox4 dysfunction aggravates atherosclerosis by inducing endoplasmic reticulum stress and soluble epoxide hydrolase.
Endothelial Nox4-based NADPH oxidase regulates atherosclerosis via soluble epoxide hydrolase.
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(-/-) mice.
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.
Soluble epoxide hydrolase in atherosclerosis.
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.
Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.
The phosphatase activity of soluble epoxide hydrolase regulates ATP-binding cassette transporter-A1-dependent cholesterol efflux.
The soluble epoxide hydrolase determines cholesterol homeostasis by regulating AMPK and SREBP activity.
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.
Atrial Fibrillation
Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation.
Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation.
Bone Resorption
Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.
Brain Edema
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Brain Injuries
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.
Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.
Brain Injuries, Traumatic
Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: Effects of traumatic brain injury.
Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury.
Brain Ischemia
Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia.
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Soluble epoxide hydrolase gene deletion improves blood flow and reduces infarct size after cerebral ischemia in reproductively senescent female mice.
Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.
Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.
Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia.
Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection.
Breast Neoplasms
Breast cancer: role of polymorphisms in biotransformation enzymes.
Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Peroxisome proliferator-activated receptor ? (PPAR?)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER?+?PR?+?HER2- breast cancer.
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Carcinogenesis
Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy.
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Average-12.9 chromosome imbalances coupling with 15 differential expression genes possibly involved in the carcinogenesis, progression and metastasis of supraglottic laryngeal squamous cell cancer.
Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.
Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis.
Immunohistochemical study of epoxide hydrolase during experimental liver carcinogenesis.
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Modulation of carcinogen metabolizing enzymes by chromanone A; a new chromone derivative from algicolous marine fungus Penicillium sp.
Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.
Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo.
Regulation of microsomal, xenobiotic epoxide hydrolase messenger RNA in persistent hepatocyte nodules and hepatomas induced by chemical carcinogens.
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Carcinoma
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Altered patterns of cutaneous xenobiotic metabolism in UVB-induced squamous cell carcinoma in SKH-1 hairless mice.
Cytochrome P450 expression in oesophageal cancer.
Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China.
Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis.
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Inhibition of Pancreatic Carcinoma Growth Through Enhancing ?-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.
Levels of cytochrome P-450, steroidogenesis and microsomal and cytosolic epoxide hydrolases in normal human adrenal tissue and corresponding tumors.
Monooxygenase, epoxide hydrolase, and glutathione-S-transferase activities in human lung. Variation between groups of bronchogenic carcinoma and non-cancer patients and interindividual differences.
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.
Carcinoma, Bronchogenic
Monooxygenase, epoxide hydrolase, and glutathione-S-transferase activities in human lung. Variation between groups of bronchogenic carcinoma and non-cancer patients and interindividual differences.
Carcinoma, Hepatocellular
Acquired risk factors and susceptibility to environmental toxicants.
Detection of epoxide hydrolase in rat hepatoma cell lines and primary rat liver cells by immunoblotting.
Diethylstilbestrol potentiates and testosterone antagonizes the action of 3-methylcholanthrene on benzo(a)pyrene metabolism in Hep G2 cells.
Effects of various enzyme inducers on monooxygenase, glutathione S-transferase and epoxide hydrolase activities in cultured hepatoma cells.
Epoxide hydrolase: a marker for experimental hepatocarcinogenesis.
Evaluation of a human hepatoma cell line as a target cell in genetic toxicology.
Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepatoma cells.
Expression of microsomal and cytosolic epoxide hydrolases in cultured rat hepatocytes and hepatoma cell lines.
Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Induction of epoxide hydrolase in cultured rat hepatocytes and hepatoma cell lines.
LINC00205 modulates the expression of EPHX1 through the inhibition of miR-184 in hepatocellular carcinoma as a ceRNA.
Quantiation of epoxide hydrolase released from hyperplastic nodule and hepatoma microsomes.
Regulation of microsomal, xenobiotic epoxide hydrolase messenger RNA in persistent hepatocyte nodules and hepatomas induced by chemical carcinogens.
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
Serum epoxide hydrolase (preneoplastic antigen) in human and experimental liver injury.
Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1.
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma.
The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol.
[Study on epoxide hydrolase in rat hyperplastic nodule and hepatoma during chemical hepatocarcinogenesis induced by 2-acetylaminofluorene (author's transl)]
Carcinoma, Squamous Cell
Altered patterns of cutaneous xenobiotic metabolism in UVB-induced squamous cell carcinoma in SKH-1 hairless mice.
Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis.
Carcinoma, Transitional Cell
SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan.
Cardio-Renal Syndrome
Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome.
Cardiomegaly
3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats.
Activation of Peroxisome Proliferator-Activated Receptor ? Downregulates Soluble Epoxide Hydrolase in Cardiomyocytes.
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line.
Deletion of Soluble Epoxide Hydrolase Attenuates Cardiac Hypertrophy via Down-Regulation of Cardiac Fibroblasts-Derived Fibroblast Growth Factor-2.
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Inhibition of Soluble Epoxide Hydrolase Confers Cardioprotection and Prevents Cardiac Cytochrome P450 Induction by Benzo(a)pyrene.
Linking an insect enzyme to hypertension: angiotensin II-epoxide hydrolase interactions.
Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis.
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.
Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition.
Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy.
The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.
Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.
Cardiomyopathies
Soluble epoxide hydrolase and ischemic cardiomyopathy.
Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.
Cardiomyopathy, Dilated
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Cardiotoxicity
Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats.
Deficiency of Soluble Epoxide Hydrolase Protects Cardiac Function Impaired by LPS-Induced Acute Inflammation.
The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.
Cardiovascular Diseases
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.
Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.
Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced diabetes.
Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.
Design, Synthesis and Biological Activity of 4,6-disubstituted Pyridin-2(1H)-ones as Novel Inhibitors of Soluble Epoxide Hydrolase.
Discovery of soluble epoxide hydrolase inhibitors through DNA-encoded library technology (ELT).
Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study.
Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans.
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
In vitro and in silico investigation of anthocyanin derivatives as soluble epoxide hydrolase inhibitors.
In Vitro and In Silico Studies of Soluble Epoxide Hydrolase Inhibitors from the Roots of Lycopus lucidus.
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis.
No impact of soluble epoxide hydrolase rs4149243, rs2234914 and rs751142 genetic variants on the development of type II diabetes and its hypertensive complication among Jordanian patients.
Novel Role of Soluble Epoxide Hydrolase in Regulating Cholesterol in Mammalian Cells.
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
Soluble epoxide hydrolase inhibition modulates vascular remodeling.
Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases.
Soluble Epoxide Hydrolase Inhibitory Activity of Selaginellin Derivatives from Selaginella tamariscina.
Soluble epoxide hydrolase: a new target for cardioprotection.
Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPAR?/STAT1 Signaling Pathway.
The left ventricle proteome differentiates middle-aged and old left ventricles in mice.
The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease.
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
[Cardiovascular consequences of chronic kidney disease, impact of modulation of epoxyeicosatrienoic acids].
Carotid Artery Diseases
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Carotid Stenosis
Soluble epoxide hydrolase inhibition alleviated cognitive impairments via NRG1/ErbB4 signaling after chronic cerebral hypoperfusion induced by bilateral carotid artery stenosis in mice.
Cerebral Hemorrhage
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Cerebral Infarction
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
Chorioamnionitis
Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis.
The anti-inflammatory role of placental Hofbauer cells is altered in patients with chorioamnionitis: Are CYP2C8 and soluble epoxide hydrolase involved in immunomodulation?
Colitis
Epoxy-Oxylipins and Soluble Epoxide Hydrolase Metabolic Pathway as Targets for NSAID-Induced Gastroenteropathy and Inflammation-Associated Carcinogenesis.
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
Colitis, Ulcerative
Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression.
Colonic Neoplasms
Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.
Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer.
Synthesis, docking, cytotoxicity, and LTA4H inhibitory activity of new gingerol derivatives as potential colorectal cancer therapy.
Colorectal Neoplasms
Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population.
Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer.
Coronary Artery Disease
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.
Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking.
Coronary Disease
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
[Effect of soluble epoxide hydrolase inhibitor on the function of endothelial progenitor cells in patients with coronary heart disease.]
Crohn Disease
Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase.
Cystic Fibrosis
Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor: Crystallographic Snapshots of an Epoxide Hydrolase.
Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor.
Epoxide-Mediated CifR Repression of cif Gene Expression Utilizes Two Binding Sites in Pseudomonas aeruginosa.
Pseudomonas aeruginosa Cif Defines a Distinct Class of ?/? Epoxide Hydrolases Utilizing a His/Tyr Ring-Opening Pair.
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.
Cysts
Inhibition of catalase and epoxide hydrolase by the renal cystogen 2-amino-4,5-diphenylthiazole and its metabolites.
Dehydration
Characterization of an Arabidopsis cDNA for a soluble epoxide hydrolase gene that is inducible by auxin and water stress.
Dementia
Antibody Protection against Long-Term Memory Loss Induced by Monomeric C-Reactive Protein in a Mouse Model of Dementia.
Diabetes Mellitus
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Mapping the genetic basis of diabetes mellitus in the Australian Burmese cat (Felis catus).
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetes Mellitus, Type 1
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients.
Association of EPHX2 R287Q Polymorphism with Diabetic Nephropathy in Chinese Type 2 Diabetic Patients.
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects.
Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes.
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetic Cardiomyopathies
Proteomic analysis of hearts from akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy.
Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy.
Diabetic Nephropathies
Association of EPHX2 R287Q Polymorphism with Diabetic Nephropathy in Chinese Type 2 Diabetic Patients.
Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy.
Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats.
The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.
Diabetic Neuropathies
Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Diabetic Retinopathy
Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy.
Dyslipidemias
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia.
Encephalomyelitis
A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Encephalomyelitis, Autoimmune, Experimental
A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Epilepsy
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Epilepsy, Temporal Lobe
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Erectile Dysfunction
Erectogenic and Aphrodisiac Property of Moringa oleifera: Involvement of Soluble Epoxide Hydrolase Enzyme.
Esophageal Neoplasms
Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India.
Esophageal Squamous Cell Carcinoma
Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China.
Essential Hypertension
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease.
Relationship between EPHX2 gene polymorphisms and essential hypertension in Uygur, Kazakh, and Han.
[Relationship between EPHX2 gene polymorphism and essential hypertension in Kazaks and Hans in Xinjiang].
Eye Diseases
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.
Fatty Liver
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.
Fetal Diseases
Phenytoin embryopathy: effect of epoxide hydrolase inhibitor on phenytoin exposure in utero in C57BL/6J mice.
Glioblastoma
?-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway.
Glomerulonephritis
In-vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.
Glomerulonephritis, IGA
Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy.
In-vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.
Glucose Intolerance
6D.05: ENDOTHELIAL DYSFUNCTION IN ANIMAL MODELS OF GLUCOSE INTOLERANCE AND DIABETES IS ACCOMPANIED BY DIFFERENT EXPRESSION OF KEY ENZYMES OF EPOXYEICOSATRIENOIC ACIDS PATHWAY.
Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.
Hearing Loss
[Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].
Heart Arrest
Neurologic effects of short-term treatment with a soluble epoxide hydrolase inhibitor after cardiac arrest in pediatric swine.
Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice.
Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.
Heart Failure
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.
Evaluation of the Effects of Urotensin II and Soluble Epoxide Hydrolase Inhibitor on Skin Microvessel Tone in Healthy Controls and Heart Failure Patients.
Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.
NADPH Oxidase 4 Regulates Inflammation in Ischemic Heart Failure: Role of Soluble Epoxide Hydrolase.
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
Sex-linked differences in the mortality in Ren-2 transgenic hypertensive rats with aorto-caval fistula: effects of treatment with angiotensin converting enzyme alone and combined with inhibitor of soluble epoxide hydrolase.
Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure.
Soluble Epoxide Hydrolase Inhibitors and Heart Failure.
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease.
HELLP Syndrome
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia.
Hepatitis B
Acquired risk factors and susceptibility to environmental toxicants.
Hydrocephalus
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Hyperalgesia
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.
Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pain mouse model.
Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation.
The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain.
Hypercholesterolemia
Evidence for the role of EPHX2 gene variants in anorexia nervosa.
Hyperemia
Deletion of Soluble Epoxide Hydrolase Enhances Coronary Reactive Hyperemia in Isolated Mouse Heart: Role of Oxylipins and PPAR?.
Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPAR?.
Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A2A receptor and plasma oxylipins.
Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ?-Hydroxylases.
Hyperglycemia
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis.
Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia.
Hyperlipoproteinemia Type II
Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.
Hypersensitivity
Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect.
Carbamazepine hypersensitivity syndrome triggered by a human herpes virus reactivation in a genetically predisposed patient.
Hypertension
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats.
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
Anti-inflammatory Effects of ?-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II-Dependent Hypertension.
Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.
Association of Epoxide Hydrolase 2 Gene Arg287Gln with the Risk for Primary Hypertension in Chinese.
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Design, Synthesis and Biological Activity of 4,6-disubstituted Pyridin-2(1H)-ones as Novel Inhibitors of Soluble Epoxide Hydrolase.
Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitors.
Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.
Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.
Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.
Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension.
Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.
Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-?(12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring.
Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.
Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
Expression of the human soluble epoxide hydrolase in Escherichia coli by auto-induction for the study of high-throughput inhibition assays.
Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an ?-linolenic acid-induced inhibition of soluble epoxide hydrolase.
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies.
Gene expression in the adrenal glands of three spontaneously hypertensive rat substrains.
Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.
Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase.
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening.
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea.
In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Incorporation of Piperazino Functionality into 1,3-Disubstituted Urea as the Tertiary Pharmacophore Affording Potent Inhibitors of Soluble Epoxide Hydrolase with Improved Pharmacokinetic Properties.
Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.
Inhibition of soluble epoxide hydrolase offers protection against fructose-induced diabetes and related metabolic complications in rats.
Inhibition of the soluble epoxide hydrolase by tyrosine nitration.
Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins.
Isothermal Titration Calorimetry Enables Rapid Characterization of Enzyme Kinetics and Inhibition for the Human Soluble Epoxide Hydrolase.
Linking an insect enzyme to hypertension: angiotensin II-epoxide hydrolase interactions.
Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?
Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.
Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?
No impact of soluble epoxide hydrolase rs4149243, rs2234914 and rs751142 genetic variants on the development of type II diabetes and its hypertensive complication among Jordanian patients.
Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors.
Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat.
Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.
Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single- and Multiple-Dose Studies in Healthy Human Subjects.
Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase.
Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase.
Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension.
Reprogramming: A Preventive Strategy in Hypertension Focusing on the Kidney.
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.
Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.
Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension.
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery.
Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography.
Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase.
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation.
Tetramethylpyrazine suppresses angiotensin II-induced soluble epoxide hydrolase expression in coronary endothelium via anti-ER stress mechanism.
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.
The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension.
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
Whole rat DNA array survey for candidate genes related to hypertension in kidneys from three spontaneously hypertensive rat substrains at two stages of age and with hypotensive induction caused by hydralazine hydrochloride.
[Expression and role of soluble epoxide hydrolase in renal tissue of two kidneys one clip hypertension rats model].
[Renal over expression of soluble epoxide hydrolase in rat with hypertension induced by high-salt.]
Hypertension, Malignant
Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME.
Hypertension, Portal
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Hypertension, Pulmonary
EET-dependent potentiation of pulmonary arterial pressure: sex-different regulation of soluble epoxide hydrolase.
Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.
Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.
Sexually Dimorphic Regulation of EET Synthesis and Metabolism: Roles of Estrogen.
Hypertension, Renovascular
Soluble Epoxide Hydrolase Inhibition Exhibits Antihypertensive Actions Independently of Nitric Oxide in Mice with Renovascular Hypertension.
Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension.
Hypotension
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Infarction, Middle Cerebral Artery
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea Exerts Neuro-Protective Effects Against Ischemic Injury via Suppressing JNK/p38 MAPK-Mediated Mitochondrial Apoptosis Pathway.
Hyperbaric oxygenation and 20-HETE inhibition reduce stroke volume in female diabetic Sprague-Dawley rats.
Protective Effects of the Soluble Epoxide Hydrolase Inhibitor 1-Trifluoromethoxyphenyl-3-(1-Propionylpiperidin-4-yl) Urea in a Rat Model of Permanent Middle Cerebral Artery Occlusion.
Infections
Fasciola hepatica: liver microsomal membrane functions in host rat.
Overexpression of hydroperoxide lyase, peroxygenase and epoxide hydrolase in tobacco for the biotechnological production of flavours and polymer precursors.
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.
Inflammatory Bowel Diseases
Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
Soluble Epoxide Hydrolase Gene Deficiency or Inhibition Attenuates Chronic Active Inflammatory Bowel Disease in IL-10(-/-) Mice.
Insulin Resistance
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
15-deoxy-?12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.
Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans.
Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients.
Attenuation of inflammation and cellular stress-related pathways maintains insulin sensitivity in obese type I interleukin-1 receptor knockout mice on a high-fat diet.
Discovery of novel heterocyclic amide-based inhibitors: an integrative in-silico approach to targeting soluble epoxide hydrolase.
EET Agonist Rescues the Metabolic Syndrome Phenotype of HO-2 Null Mice.
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Isothermal Titration Calorimetry Enables Rapid Characterization of Enzyme Kinetics and Inhibition for the Human Soluble Epoxide Hydrolase.
Quinazoline-4(3H)-one derivatives as novel and potent inhibitors of soluble epoxide hydrolase: Design, synthesis and biological evaluation.
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Ischemic Stroke
Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation.
CYP2C8 rs17110453 and EPHX2 rs751141 two-locus interaction increases susceptibility to ischemic stroke.
Epoxyeicosatrienoic Acids are Mediated by EPHX2 Variants and may be a Predictor of Early Neurological Deterioration in Acute Minor Ischemic Stroke.
Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population.
Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans.
Genetic variation in soluble epoxide hydrolase: association with outcome after aneurysmal subarachnoid hemorrhage.
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Genetics of ischemic stroke.
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes.
Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.
Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation.
Inhibition of soluble epoxide hydrolase regulates monocyte/macrophage polarization and improves neurological outcome in a rat model of ischemic stroke.
Interaction among CYP2C8, EPHX2, and CYP4A11 Gene Variants Significantly Increases the Risk for Ischemic Stroke in Chinese Populations.
Interactions Among CYP2C8, EPHX2, and CYP4A11 Variants and CYP Plasma Metabolite Levels in Ischemic Stroke.
Ischemic Stroke and Six Genetic Variants in CRP, EPHX2, FGA, and NOTCH3 Genes: A Meta-Analysis.
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
Protection of salvianolic acid A on rat brain from ischemic damage via soluble epoxide hydrolase inhibition.
Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury.
Soluble epoxide hydrolase inhibition enhances anti-inflammatory and antioxidative processes, modulates microglia polarization, and promotes recovery after ischemic stroke.
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.
Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Soluble Epoxide Hydrolase Inhibitor trans-4-[4-(3-Adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic Acid (t-AUCB) is Neuroprotective in Rat Model of Ischemic Stroke.
Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase.
Synergistic Effect of the MTHFR C677T and EPHX2 G860A Polymorphism on the Increased Risk of Ischemic Stroke in Chinese Type 2 Diabetic Patients.
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.
Kidney Diseases
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension.
Kidney Failure, Chronic
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
Leishmaniasis
Changes in hepatic xenobiotic-metabolising enzymes in mouse liver following infection with Leishmania donovani.
Leukemia
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression.
Leukotriene A4: preparation and enzymatic conversion in a cell-free system to leukotriene B4.
Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo.
Liver Cirrhosis
Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Liver Cirrhosis, Alcoholic
The effect of alcoholic cirrhosis on the activities of microsomal aldrin epoxidase, 7-ethoxycoumarin O-de-ethylase and epoxide hydrolase, and on the concentrations of reduced glutathione in human liver.
Liver Diseases
Soluble Epoxide Hydrolase Hepatic Deficiency Ameliorates Alcohol-Associated Liver Disease.
Soluble Epoxide Hydrolase Inhibition in Liver Diseases: A Review of Current Research and Knowledge Gaps.
Liver Neoplasms
Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.
Lung Diseases
Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.
Lung Injury
Alleviation of lung injury by glycyrrhizic acid in benzo(a)pyrene exposed rats: Probable role of soluble epoxide hydrolase and thioredoxin reductase.
Soluble Epoxide Hydrolase Plays a Vital role In Angiotensin II-Induced Lung Injury in Mice.
Lung Neoplasms
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer.
Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer.
Genetic Polymorphism of Epoxide Hydrolase and GSTM1 in Lung Cancer Susceptibility of Korean Population.
Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers.
Hierarchical modeling identifies novel lung cancer susceptibility variants in inflammation pathways among 10,140 cases and 11,012 controls.
Impact of epoxide hydrolase 1 polymorphisms on lung cancer susceptibility in asian populations.
[Role of ancestral genotypes of the genes of xenobiotics biotransformation in susceptibility to lung cancer among Mayak workers].
Lupus Nephritis
Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.
Lymphatic Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma
Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Lymphoma, B-Cell
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Metabolic Diseases
Diabetic CVD - Soluble Epoxide Hydrolase as A Target.
Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue.
Soluble epoxide hydrolase: A potential target for metabolic diseases.
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Metabolic Syndrome
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Eicosanoids and renal damage in cardiometabolic syndrome.
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.
The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease.
Zafirlukast Is a Dual Modulator of Human Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptor ?.
MPTP Poisoning
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Mucocutaneous Lymph Node Syndrome
The Anti-inflammatory Effect of Soluble Epoxide Hydrolase Inhibitor and 14, 15-EET in Kawasaki Disease Through PPAR?/STAT1 Signaling Pathway.
Multiple Myeloma
Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma.
Multiple Sclerosis
Development of Improved Double-Nanobody Sandwich ELISAs for Human Soluble Epoxide Hydrolase Detection in Peripheral Blood Mononuclear Cells of Diabetic Patients and the Prefrontal Cortex of Multiple Sclerosis Patients.
Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.
Myocardial Infarction
A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPAR? to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.
A Soluble Epoxide Hydrolase Inhibitor Upregulated KCNJ12 and KCNIP2 by Downregulating MicroRNA-29 in a Mouse Model of Myocardial Infarction.
Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: Roles of the NF-?B and MAPK signaling pathways.
Genetic deletion of soluble epoxide hydrolase provides cardioprotective responses following myocardial infarction in aged mice.
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Soluble epoxide hydrolase inhibitors improve angiogenic function of endothelial progenitor cells via ERK/p38-mediated miR-126 upregulation in myocardial infarction mice after exercise.
Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction.
Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice.
Myocardial Ischemia
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Myocardial Stunning
Soluble epoxide hydrolase: a new target for cardioprotection.
Neoplasm Metastasis
Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression.
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.
Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
Neoplasms
6-Gingerol abates benzo[a]pyrene-induced colonic injury via suppression of oxido-inflammatory stress responses in BALB/c mice.
Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy.
Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression.
Bioactive Hydroperoxyl Cembranoids from the Red Sea Soft Coral Sarcophyton glaucum.
Carcinogenesis: Failure of resolution of inflammation?
Clinical significance of EPHX2 deregulation in prostate cancer.
Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth.
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.
Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.
Cytochrome P-450 isozyme pattern is related to individual susceptibility to diethylnitrosamine-induced liver cancer in rats.
Cytochrome P450 expression in oesophageal cancer.
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms.
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.
Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures.
Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype.
Epoxide hydrolase: a marker for experimental hepatocarcinogenesis.
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice.
Expression of xenobiotic metabolizing enzymes in breast cancer.
Expression of xenobiotic metabolizing enzymes in tumours of the urinary bladder.
Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man.
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers.
Heavy chain single-domain antibodies to detect native human soluble epoxide hydrolase.
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates.
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
LINC00205 modulates the expression of EPHX1 through the inhibition of miR-184 in hepatocellular carcinoma as a ceRNA.
Localization of microsomal epoxide hydrolase in normal and neoplastic human kidney.
Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues.
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.
Mechanisms of fat-related modulation of N-nitrosodiethylamine-induced tumors in rats: organ distribution, blood lipids, enzymes and pro-oxidant state.
Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome p450s and epoxide hydrolase in its biotransformation.
Modulation of carcinogen metabolizing enzymes by new fused heterocycles pendant to 5,6,7,8-tetrahydronaphthalene derivatives.
Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?
Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma.
Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma.
Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency.
Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.
Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.
Species differences in the hydrolysis of 2-cyanoethylene oxide, the epoxide metabolite of acrylonitrile.
The Consequences of Soluble Epoxide Hydrolase Deletion on Tumorigenesis and Metastasis in a Mouse Model of Breast Cancer.
The cytochrome P450 pathway in angiogenesis and endothelial cell biology.
The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma.
The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer.
Xenobiotic metabolising enzyme expression in colonic neoplasia.
Xenobiotic metabolizing enzymes in genetically and chemically initiated mouse liver tumors.
Nephritis
Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.
Nervous System Diseases
Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders.
Neural Tube Defects
Pharmacogenetic screening for susceptibility to fetal malformations in women.
Neuralgia
Comparing Gene Expression in the Parabrachial and Amygdala of Diestrus and Proestrus Female Rats after Orofacial Varicella Zoster Injection.
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.
In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea.
Lack of rewarding effects of a soluble epoxide hydrolase inhibitor TPPU in mice: Comparison with morphine.
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE? induced pain model.
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.
Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.
Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis.
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Neurodegenerative Diseases
Natural soluble epoxide hydrolase inhibitors from Inula britanica and their potential interactions with soluble epoxide hydrolase: Insight from inhibition kinetics and molecular dynamics.
Proteomics and bioinformatics analysis of mouse hypothalamic neurogenesis with or without EPHX2 gene deletion.
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.
Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain.
Neuroinflammatory Diseases
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease.
Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury.
Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.
First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET.
Genetic deletion or pharmacological inhibition of soluble epoxide hydrolase reduces brain damage and attenuates neuroinflammation after intracerebral hemorrhage.
Inhibition of soluble epoxide hydrolase regulates monocyte/macrophage polarization and improves neurological outcome in a rat model of ischemic stroke.
Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication.
Single administration of soluble epoxide hydrolase inhibitor suppresses neuroinflammation and improves neuronal damage after cardiac arrest in mice.
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Soluble epoxide hydrolase modulates immune responses in activated astrocytes involving regulation of STAT3 activity.
Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain.
Niemann-Pick Disease, Type C
Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease.
Non-alcoholic Fatty Liver Disease
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease.
Obesity
1-trifluoromethoxyphenyl-3(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor attenuates high fat diet-induced cardiovascular and metabolic disorders in rats.
A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases.
Differential Effects of 17,18-EEQ and 19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice.
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.
Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue.
High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression.
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Obesity is positively associated with arachidonic acid-derived 5- and 11-hydroxyeicosatetraenoic acid (HETE).
Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice.
Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats.
Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.
Soluble Epoxide Hydrolase 2 Expression Is Elevated in Obese Humans and Decreased by Physical Activity.
Soluble Epoxide Hydrolase Inhibition by t-TUCB Promotes Brown Adipogenesis and Reduces Serum Triglycerides in Diet-Induced Obesity.
The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Obesity, Maternal
Genetic polymorphisms in neuroendocrine disorder-related candidate genes associated with pre-pregnancy obesity in gestational diabetes mellitus patients by using a stratification approach.
Oligospermia
Genetic variants in epoxide hydrolases modify the risk of oligozoospermia and asthenospermia in Han-Chinese population.
Osteoarthritis
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis.
Osteoarthritis, Knee
Omega-6 oxylipins generated by soluble epoxide hydrolase are associated with knee osteoarthritis.
Ovarian Neoplasms
A long-wavelength, fluorogenic probe for epoxide hydrolase: 7-(2-(oxiran-2-yl)ethoxy) resorufin.
Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.
Overweight
Addition of milk fat globule membrane-enriched supplement to a high-fat meal attenuates insulin secretion and induction of soluble epoxide hydrolase gene expression in the postprandial state in overweight and obese subjects.
Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Pancreatic Diseases
The role of epoxide hydrolase Y113H gene variant in pancreatic diseases.
Pancreatitis
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis.
Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice.
From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis.
Soluble epoxide hydrolase deficiency ameliorates acute pancreatitis in mice.
Soluble Epoxide Hydrolase Pharmacological Inhibition Ameliorates Experimental Acute Pancreatitis in Mice.
Pancreatitis, Chronic
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Parkinson Disease
Contribution of DHA diols (19,20-DHDP) produced by cytochrome P450s and soluble epoxide hydrolase to the beneficial effects of DHA supplementation in the brains of rotenone-induced rat models of Parkinson's disease.
Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease.
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease.
Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Peripheral Arterial Disease
Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an ?-linolenic acid-induced inhibition of soluble epoxide hydrolase.
Peroxisomal Disorders
Epoxide hydrolase in human and rat peroxisomes: implication for disorders of peroxisomal biogenesis.
Pneumonia
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.
Soluble Epoxide Hydrolase Inhibitor Attenuates Inflammation and Airway Hyperresponsiveness in Mice.
Polycystic Kidney Diseases
Protective effect of Soluble Epoxide Hydrolase Inhibition in Retinal Vasculopathy associated with Polycystic Kidney Disease.
Polyneuropathies
Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case-control study.
Pre-Eclampsia
A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia.
Association between the soluble epoxide hydrolase gene and preeclampsia.
Association of microsomal epoxide hydrolase gene polymorphism and pre-eclampsia in Turkish women.
Association of the sEH gene promoter polymorphisms and haplotypes with preeclampsia.
Genetic Polymorphism of Microsomal Epoxide Hydrolase Enzyme Gene in Preeclamptic Females.
Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa.
PP057. ENOSI4 and EPHX1 polymorphisms affect maternal susceptibility topreeclampsia - Analysis of five polymorphisms predisposing tocardiovascular disease in 279 caucasian and 241 african women.
Susceptibility to pre-eclampsia is associated with multiple genetic polymorphisms in maternal biotransformation enzymes.
The role of soluble epoxide hydrolase in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.
Prostatic Neoplasms
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Clinical significance of EPHX2 deregulation in prostate cancer.
Protein Deficiency
Effect of a dietary protein deficiency on the development of hepatic drug-metabolizing enzymes in young rats.
Proteinuria
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Psoriasis
Aryl hydrocarbon hydroxylase, epoxide hydrolase, and benzo[a]-pyrene metabolism in human epidermis: comparative studies in normal subjects and patients with psoriasis.
Pulmonary Disease, Chronic Obstructive
Cigarette Smoke-Induced Pulmonary Inflammation and Autophagy Are Attenuated in Ephx2-Deficient Mice.
Exploration of association between EPHX1 and chronic obstructive pulmonary disease on the basis of combined data mining.
Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD.
Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase.
Use of a Soluble Epoxide Hydrolase Inhibitor in Smoke-Induced Chronic Obstructive Pulmonary Disease.
Pulmonary Fibrosis
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Erratum to: Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.
Inula japonica ameliorated bleomycin-induced pulmonary fibrosis via inhibiting soluble epoxide hydrolase.
Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.
Renal Insufficiency, Chronic
Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats.
Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease.
Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
Discovery of 1-oxa-4,9-diazaspiro[5.5]undecane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating of chronic kidney diseases.
Eicosanoids and renal damage in cardiometabolic syndrome.
Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.
Mechanism of Chronic Kidney Disease Progression and Novel Biomarkers: A Metabolomic Analysis of Experimental Glomerulonephritis.
Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.
Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3? signaling pathway.
Reperfusion Injury
Early antihypertensive treatment and ischemia-induced acute kidney injury.
In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase.
Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) is protective against ischemia reperfusion injury.
Soluble epoxide hydrolase activation by S-nitrosation contributes to cardiac ischemia-reperfusion injury.
Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney.
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Respiratory Distress Syndrome
Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Retinopathy of Prematurity
Soluble epoxide hydrolase promotes astrocyte survival in retinopathy of prematurity.
Sarcoidosis
Soluble epoxide hydrolase derived lipid mediators are elevated in bronchoalveolar lavage fluid from patients with sarcoidosis: a cross-sectional study.
Scrapie
Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.
Seizures
Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model.
Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures.
Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication.
Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.
Sepsis
Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Prolonged Soluble Epoxide Hydrolase Reactivity in Brain Endothelial Cells Is Associated with Long Cognitive Deficits in Sepsis.
Shock, Septic
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
soluble epoxide hydrolase deficiency
Effects of soluble epoxide hydrolase deficiency on acute pancreatitis in mice.
Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.
Soluble epoxide hydrolase deficiency ameliorates acute pancreatitis in mice.
Soluble epoxide hydrolase deficiency attenuates lipotoxic cardiomyopathy via upregulation of AMPK-mTORC mediated autophagy.
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.
Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue.
Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.
Soluble epoxide hydrolase deficiency or inhibition enhances murine hypoxic pulmonary vasoconstriction after lipopolysaccharide challenge.
Spinal Cord Injuries
Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.
Squamous Cell Carcinoma of Head and Neck
Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma.
Starvation
Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases, glutathione S-transferases and peroxisomal beta-oxidation.
Preparation and characterization of subcellular fractions from the liver of C57B1/6 mice, with special emphasis on their suitability for use in studies of epoxide hydrolase activities.
Stomach Ulcer
Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.
Stroke
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation.
Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease.
Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.
Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke.
Mechanism of the sex difference in endothelial dysfunction after stroke.
Missense Genetic Polymorphisms of Microsomal (EPHX1) and Soluble Epoxide Hydrolase (EPHX2) and Their Relation to the Risk of Large Artery Atherosclerotic Ischemic Stroke in a Turkish Population.
Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury.
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP.
Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.
Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus.
Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.
Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice.
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Subarachnoid Hemorrhage
Genetic variation in soluble epoxide hydrolase: association with outcome after aneurysmal subarachnoid hemorrhage.
Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage.
Synovitis
Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis.
Tachycardia
5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKK?/I?B-?/NF-?B pathway, and proinflammatory cytokine formation.
Genetic variants associated with atrial fibrillationand long-term recurrence after catheter ablation for atrialfibrillation in Turkish patients.
Thrombocytopenia
Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism.
Thrombosis
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Triple Negative Breast Neoplasms
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Tuberculosis
mesT, a unique epoxide hydrolase, is essential for optimal growth of Mycobacterium tuberculosis in the presence of styrene oxide.
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
Structure of an atypical epoxide hydrolase from Mycobacterium tuberculosis gives insights into its function.
The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
Ureteral Obstruction
Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis.
Urinary Bladder Neoplasms
Toxic action/toxicity.
Uveitis
Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.
Vaccinia
2,3-epoxy-4-hydroxynonanal, a potential lipid peroxidation product for etheno adduct formation, is not a substrate of human epoxide hydrolase.
Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol.
Vascular Calcification
The Metabolism of Epoxyeicosatrienoic Acids by Soluble Epoxide Hydrolase Is Protective against the Development of Vascular Calcification.
Vascular Diseases
Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.
Cytochrome P450 eicosanoids and cerebral vascular function.
Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future.
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Vascular System Injuries
Soluble epoxide hydrolase inhibition modulates vascular remodeling.